Japan presents huge opportunities for new product launches, but Western companies often squander them, failing to understand the unique aspects and requirements of the market. They often mis-estimate the size of commercial opportunities in Japan because of the differences in epidemiology and medical practice or run into pricing problems because they've chosen the wrong local comparator product or ignored the Japanese tendency to prescribe lower doses of products. But Westerners can do better--taking advantage, for example, of the liberalization of development rules and even the possibility of DTC advertising.
by Michael Devlin, Cynthia Kaufman, Frederic Mascha and Joe
Watson
Even at this late date in the globalization of the pharmaceutical industry, the world's second largest market—Japan—continues to flummox many...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
